SULLIVAN CHRISTOPHER RYAN (Interim CFO) sold 97.8% of their position (18.61K shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $448.8K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 5/11/2026ACC: 0001810417-26-000012
Officer· Interim CFO
Since Apr 2020
-18.61K
Net shares
Net seller
$448.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
18.61K acquired · 37.21K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+18.61K
Price / share
$9.88
Trade value
$183.83K
% of position
4398.6%
5/7/2026
423.00→19.03K
Common Stock
Direct
Shares
−18.61K
Price / share
$24.12
Trade value
$448.82K
% of position
97.8%
5/7/2026
19.03K→423.00
Total
Net shares
+0.00
Net value
-$264.99K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/7/2026 | M · Option Exercise | +18.61K | $9.88 | $183.83K | 4398.6% | 423.00 | 19.03K |
| Common Stock Direct | 5/7/2026 | S · Sale | −18.61K | $24.12 | $448.82K | 97.8% | 19.03K | 423.00 |
| Total | +0.00 | -$264.99K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
18.61K shares
Shares
−18.61K
Strike price
9.88
Held after
168.09K
Exercisable
—
5/7/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock18.61K shares | 5/7/2026 | M · Option Exercise | −18.61K | 9.88 | — | 168.09K |